Erlotinib for Japanese Patients with Activating EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Combined Analyses from Two Phase II Studies
S Atagi, K Goto, T Seto, N Yamamoto, T Tamura… - Future …, 2016 - Taylor & Francis
Aims: We evaluated the efficacy and safety of erlotinib, and patient characteristics affecting
progression-free survival (PFS), by analyzing data from two Phase II studies of first-line …
progression-free survival (PFS), by analyzing data from two Phase II studies of first-line …
Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer
N Yamamoto, K Goto, M Nishio, K Chikamori… - International Journal of …, 2017 - Springer
Abstract Background In Japan, the clinical efficacy of erlotinib monotherapy in epidermal
growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer was …
growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer was …
[HTML][HTML] A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive …
K Goto, M Nishio, N Yamamoto, K Chikamori, T Hida… - Lung Cancer, 2013 - Elsevier
Introduction The epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor erlotinib
is associated with survival benefits in patients with EGFR mutation-positive non-small-cell …
is associated with survival benefits in patients with EGFR mutation-positive non-small-cell …
Phase II Trial of Erlotinib for Japanese Patients With Previously Treated Non-small-cell Lung Cancer Harboring EGFR Mutations: Results of Lung Oncology Group in …
K Yamada, K Takayama, S Kawakami… - Japanese journal of …, 2013 - academic.oup.com
Objective Erlotinib has been reported to be useful for treatment of non-small-cell lung cancer
harboring mutation of the epidermal growth factor receptor gene EGFR-mt. However, no …
harboring mutation of the epidermal growth factor receptor gene EGFR-mt. However, no …
A phase II trial of erlotinib as front-line treatment in clinically selected patients with non–small-cell lung cancer
AG Pallis, A Voutsina, N Kentepozidis, S Giassas… - Clinical Lung Cancer, 2012 - Elsevier
Background The purpose of this study was to evaluate the efficacy of erlotinib as front-line
treatment in clinically selected patients with non–small-cell lung cancer (NSCLC). Patients …
treatment in clinically selected patients with non–small-cell lung cancer (NSCLC). Patients …
[HTML][HTML] Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced …
C Zhou, YL Wu, G Chen, J Feng, XQ Liu, C Wang… - Annals of …, 2015 - Elsevier
Background The OPTIMAL study was the first study to compare efficacy and tolerability of the
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus …
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus …
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a …
C Zhou, YL Wu, G Chen, J Feng, XQ Liu… - The lancet …, 2011 - thelancet.com
Background Activating mutations in EGFR are important markers of response to tyrosine
kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study …
kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study …
Prospective evaluation of first-line erlotinib in advanced non-small cell lung cancer (NSCLC) carrying an activating EGFR mutation: A multicenter academic phase II …
J De Grève, J Van Meerbeeck, JF Vansteenkiste… - PLoS …, 2016 - journals.plos.org
Introduction Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibition is the
preferred first-line treatment of advanced adenocarcinoma of the lung that harbors EGFR …
preferred first-line treatment of advanced adenocarcinoma of the lung that harbors EGFR …
First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation …
K Park, CJ Yu, SW Kim, MC Lin, V Sriuranpong… - JAMA …, 2016 - jamanetwork.com
Importance Continuing molecularly targeted treatment beyond disease progression in non–
small-cell lung cancer (NSCLC) has appeared promising in retrospective analyses …
small-cell lung cancer (NSCLC) has appeared promising in retrospective analyses …
[HTML][HTML] A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama …
H Yoshioka, K Hotta, K Kiura, N Takigawa… - Journal of Thoracic …, 2010 - Elsevier
Backgrounds Efficacy of gefitinib therapy strongly depends on epidermal growth factor
receptor (EGFR)-mutation status in Asian patients with non-small cell lung cancer. Recently …
receptor (EGFR)-mutation status in Asian patients with non-small cell lung cancer. Recently …
相关搜索
- cell lung cancer patients
- egfr mutations lung cancer
- egfr mutations japanese patients
- combined analyses lung cancer
- erlotinib for japanese patients
- combined analyses japanese patients
- phase ii trial of erlotinib
- egfr mutations multicentre phase
- prospective evaluation egfr mutation
- caucasian patients prospective evaluation
- japanese patients lung cancer
- caucasian patients egfr mutation